Literature DB >> 28185131

External validation of a claims-based and clinical approach for predicting post-pulmonary embolism outcomes among United States veterans.

Christine G Kohn1, Erin R Weeda2, Neela Kumar3, Philip S Wells4, W Frank Peacock5, Gregory J Fermann6, Li Wang7, Onur Baser7,8, Jeff R Schein9, Concetta Crivera9, Craig I Coleman10.   

Abstract

The In-hospital Mortality for PulmonAry embolism using Claims daTa (IMPACT) rule can accurately identify pulmonary embolism (PE) patients at low risk of early complications using claims data. We sought to externally validate the IMPACT and simplified Pulmonary Embolism Severity Index (sPESI) tools for predicting all-cause mortality and readmission. We used Veteran Health Administration data (10/1/2010-9/30/2015) to identify adults with ≥1 inpatient diagnosis code for acute PE, ≥12 months continuous medical and pharmacy benefits prior to the index PE, ≥90 days of post-event follow-up (unless death occurred) and ≥1 claim for an anticoagulant during the index PE stay. Prognostic accuracies of IMPACT and sPESI for 30- and 90-day all-cause mortality and 90-day readmission were estimated. Of 6,746 PE patients, 7.5 and 12.6% died at 30 and 90 days. Within 90 days, 20.1% were readmitted for any reason. Hospitalization for recurrent VTE and major bleeding occurred in 5.6 and 1.7% of patients. IMPACT classified 15.2% as low risk, while 28.4% were low risk per sPESI. Both tools displayed sensitivity >90% and negative predictive values (NPVs) >97% for 30-day mortality, but low specificity (range 16.2-30.0) and positive predictive values (PPVs) (range 8.7-9.5); with similar results observed for 90-day mortality. IMPACT's sensitivity for all-cause readmission was numerically higher than sPESI (88.2 vs. 79.0%), but both had comparable NPVs (85.1 vs. 84.2%). Similar trends were observed for VTE or major bleeding readmissions. IMPACT classified patients for post-PE outcomes with similar accuracy as sPESI. IMPACT appears useful for identifying PE patients at low risk for early mortality or readmission in claims-based studies.

Entities:  

Keywords:  Administrative claim; Mortality; Prognosis; Pulmonary embolism; Risk assessment; Severity of illness index

Mesh:

Year:  2017        PMID: 28185131     DOI: 10.1007/s11739-017-1625-9

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  13 in total

1.  External validation of the In-hospital Mortality for PulmonAry embolism using Claims daTa (IMPACT) multivariable prediction rule.

Authors:  C G Kohn; W F Peacock; G J Fermann; T J Bunz; C Crivera; J R Schein; C I Coleman
Journal:  Int J Clin Pract       Date:  2015-11-17       Impact factor: 2.503

2.  How VA hospitals became the best.

Authors:  Douglas Waller
Journal:  Time       Date:  2006-09-04

3.  Comorbidity measures for use with administrative data.

Authors:  A Elixhauser; C Steiner; D R Harris; R M Coffey
Journal:  Med Care       Date:  1998-01       Impact factor: 2.983

Review 4.  Prognostic accuracy of clinical prediction rules for early post-pulmonary embolism all-cause mortality: a bivariate meta-analysis.

Authors:  Christine G Kohn; Elizabeth S Mearns; Matthew W Parker; Adrian V Hernandez; Craig I Coleman
Journal:  Chest       Date:  2015-04       Impact factor: 9.410

5.  Derivation and validation of the In-hospital Mortality for PulmonAry embolism using Claims daTa (IMPACT) prediction rule.

Authors:  Craig I Coleman; Christine G Kohn; Thomas J Bunz
Journal:  Curr Med Res Opin       Date:  2015-07-17       Impact factor: 2.580

6.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.

Authors:  Clive Kearon; Elie A Akl; Joseph Ornelas; Allen Blaivas; David Jimenez; Henri Bounameaux; Menno Huisman; Christopher S King; Timothy A Morris; Namita Sood; Scott M Stevens; Janine R E Vintch; Philip Wells; Scott C Woller; Lisa Moores
Journal:  Chest       Date:  2016-01-07       Impact factor: 9.410

7.  Chapter 8: meta-analysis of test performance when there is a "gold standard".

Authors:  Thomas A Trikalinos; Cynthia M Balion; Craig I Coleman; Lauren Griffith; Pasqualina L Santaguida; Ben Vandermeer; Rongwei Fu
Journal:  J Gen Intern Med       Date:  2012-06       Impact factor: 5.128

8.  Search filters for finding prognostic and diagnostic prediction studies in Medline to enhance systematic reviews.

Authors:  Geert-Jan Geersing; Walter Bouwmeester; Peter Zuithoff; Rene Spijker; Mariska Leeflang; Karel G M Moons; Karel Moons
Journal:  PLoS One       Date:  2012-02-29       Impact factor: 3.240

9.  External validation of a multivariable claims-based rule for predicting in-hospital mortality and 30-day post-pulmonary embolism complications.

Authors:  Craig I Coleman; W Frank Peacock; Gregory J Fermann; Concetta Crivera; Erin R Weeda; Michael Hull; Mary DuCharme; Laura Becker; Jeff R Schein
Journal:  BMC Health Serv Res       Date:  2016-10-22       Impact factor: 2.655

10.  External validation of prognostic rules for early post-pulmonary embolism mortality: assessment of a claims-based and three clinical-based approaches.

Authors:  Erin R Weeda; Christine G Kohn; Gregory J Fermann; W Frank Peacock; Christopher Tanner; Daniel McGrath; Concetta Crivera; Jeff R Schein; Craig I Coleman
Journal:  Thromb J       Date:  2016-03-14
View more
  3 in total

1.  Claims-based or clinical models for predicting 90-day post-pulmonary embolism outcomes.

Authors:  Cecilia Becattini; Giancarlo Agnelli
Journal:  Intern Emerg Med       Date:  2017-05-22       Impact factor: 3.397

2.  Short-term outcomes of pulmonary embolism: A National Perspective.

Authors:  Purav Shah; Shilpkumar Arora; Varun Kumar; Surina Sharma; Harshil Shah; Byomesh Tripathi; Purnima Sharma; Ravina Sharma; Sejal Savani; Muhammad Raheel Qureshi; Ibrahim Faruqi
Journal:  Clin Cardiol       Date:  2018-09-24       Impact factor: 2.882

3.  Using Veterans Affairs Corporate Data Warehouse to identify 30-day hospital readmissions.

Authors:  Brenda M Vincent; Wyndy L Wiitala; Jennifer A Burns; Theodore J Iwashyna; Hallie C Prescott
Journal:  Health Serv Outcomes Res Methodol       Date:  2018-02-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.